Colon cancer treatment is personalized based on stage, overall health and tumor characteristics. Early detection and accurate ...

A blood-based colorectal cancer (CRC) screening test, SimpleScreen™, has shown a significant leap in performance, ...

Liquid biopsies have transformed cancer testing. These tests detect signs of cancer using a simple blood draw instead of removing tissue from the body. Traditional biopsies involve surgery, needles, ...

A new blood-based test for colorectal cancer currently up for FDA review could mean cheaper and less invasive screenings for the disease. Doctors and advocates have been waiting for years for a new ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for ...

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery, according to new study in JAMA Oncology.

The ctDNA test showed 79.2% sensitivity and 91.5% specificity for CRC detection in a diverse cohort. The study met primary end points but had limited sensitivity for advanced precancerous lesions.

This indicates that the test is as effective as colonoscopy in reducing colorectal cancer mortality in screening [programs],” ...

Guardant Health's Shield blood test for colorectal cancer screening is now covered by TRICARE, providing active duty service ...

For 10% of colorectal cancer patients, hereditary factors play a role, with higher percentages among younger patients.